These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36358694)

  • 1. Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients.
    Farina M; Chiarini M; Almici C; Accorsi Buttini E; Zuccalà F; Piva S; Volonghi I; Poli L; Bernardi S; Colnaghi F; Re F; Leoni A; Polverelli N; Turra A; Morello E; Galvagni A; Moratto D; Brugnoni D; Cattaneo C; Ferrari E; Bianchetti A; Malagola M; Re A; Russo D
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
    Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
    Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
    Piñeyroa JA; Cid J; Vlagea A; Carbassé G; Henao P; Bailo N; Ortiz-Maldonado V; Martínez-Cibrian N; Español M; Delgado J; Urbano-Ispizua Á; Lozano M
    Vox Sang; 2023 Mar; 118(3):217-222. PubMed ID: 36516201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.
    Hutt D; Bielorai B; Baturov B; Z'orbinski I; Ilin N; Adam E; Itzhaki O; Besser MJ; Toren A; Jacoby E
    Transfus Apher Sci; 2020 Aug; 59(4):102769. PubMed ID: 32414613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies.
    Thibodeaux SR; Aqui NA; Park YA; Schneiderman J; Su LL; Winters JL; Zubair AC; Schwartz J; Liu HD;
    J Clin Apher; 2022 Jun; 37(3):223-236. PubMed ID: 35085413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
    Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
    J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
    Allen ES; Stroncek DF; Ren J; Eder AF; West KA; Fry TJ; Lee DW; Mackall CL; Conry-Cantilena C
    Transfusion; 2017 May; 57(5):1133-1141. PubMed ID: 28236305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
    Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
    Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
    Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
    Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.
    Ababneh HS; Abramson JS; Johnson PC; Patel CG
    Radiother Oncol; 2022 Oct; 175():65-72. PubMed ID: 35952976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
    Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of lymphapheresis for manufacturing autologous CAR-T cells.
    Yamanaka I; Yamauchi T; Henzan T; Sakoda T; Miyamoto K; Mishima H; Ono H; Koga Y; Nakashima Y; Kato K; Miyamoto T; Mizuno S; Ogawa Y; Ohga S; Akashi K; Maeda T; Kunisaki Y
    Int J Hematol; 2021 Oct; 114(4):449-458. PubMed ID: 34275066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
    Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
    Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex Vivo Model to Assess the Exposure of Patients to Plasticizers from Medical Devices during Pre-CAR-T Cells' Apheresis.
    Lautraite R; Bernard L; Halle P; Chennell P; Le Basle Y; Kanold J; Sautou V
    Toxics; 2022 Feb; 10(2):. PubMed ID: 35202265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.